Evidence map›Paper›PMID 26336985›Full record

ArticleOncotarget2015

Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma.

Jochen K Lennerz, Karl Hoffmann, Anna-Maria Bubolz, Davor Lessel, Claudia Welke, Nele Rüther, Andreas Viardot, Peter Möller

Open access · diamondAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Genetic lesions and targeted therapy in Hodgkin lymphoma.Therapeutic advances in hematology · 2023
    Review
  6. Review
  7. Observational
  8. Negative Regulation of Cytokine Signaling in Immunity.Cold Spring Harbor perspectives in biology · 2018
    Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Jochen K LennerzUlm University, Institute of Pathology, Ulm, Germany.
Karl HoffmannUlm University, Institute of Pathology, Ulm, Germany.
Anna-Maria BubolzUlm University, Institute of Pathology, Ulm, Germany.
Davor LesselUlm University, Institute of Human Genetics, Ulm, Germany.
Claudia WelkeComprehensive Cancer Center, Ulm University, Ulm, Germany.
Nele RütherUlm University, Institute of Pathology, Ulm, Germany.
Andreas ViardotUlm University, Department of Internal Medicine III, Ulm, Germany.
Peter MöllerUlm University, Institute of Pathology, Ulm, Germany.
Universität Ulm · DEMassachusetts General Hospital · USUniversität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Suppressor of cytokine signaling 1 (SOCS1) mutations are among the most frequent somatic mutations in classical Hodgkin lymphoma (cHL), yet their prognostic relevance in cHL is unexplored. Here, we performed laser-capture microdissection of Hodgkin/Reed-Sternberg (HRS) cells from tumor samples in a cohort of 105 cHL patients. Full-length SOCS1 gene sequencing showed mutations in 61% of all cases (n = 64/105). Affected DNA-motifs and mutation pattern suggest that many of these SOCS1 mutations are the result of aberrant somatic hypermutation and we confirmed expression of mutant alleles at the RNA level. Contingency analysis showed no significant differences of patient-characteristics with HRS-cells containing mutant vs. wild-type SOCS1. By predicted mutational consequence, mutations can be separated into those with non-truncating point mutations ('minor' n = 49/64 = 77%) and those with length alteration ('major'; n = 15/64 = 23%). Subgroups did not differ in clinicopathological characteristics; however, patients with HRS-cells that contained SOCS1 major mutations suffered from early relapse and significantly shorter overall survival (P = 0.03). The SOCS1 major status retained prognostic significance in uni-(P = 0.016) and multivariate analyses (P = 0.005). Together, our data indicate that the SOCS1 mutation type qualifies as a single-gene prognostic biomarker in cHL.

Indexed as

MutationReed-Sternberg CellsAdolescentAdultAgedAged, 80 and overBiomarkers, TumorChildChi-Square DistributionDisease ProgressionDNA Mutational AnalysisFemaleGene Expression Regulation, NeoplasticGene FrequencyGenetic Predisposition to DiseaseHodgkin DiseaseBiomarkers, TumorSOCS1 protein, humanSuppressor of Cytokine Signaling 1 ProteinSuppressor of Cytokine Signaling ProteinscHLHodgkin lymphomaprognostic biomarkerSOCS1

Identifiers

PMID26336985
PMCPMC4745714
OpenAlexW1948562674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.